Evotec AG announced today that Evotec and Celgene Corporation (“Celgene”) have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
Under the terms of the agreement, Evotec will receive an upfront payment of $ 65 m and may be eligible to receive significant milestone payments as well as tiered royalties on each licensed programme. Celgene receives exclusive opt-in rights to license worldwide rights to all programmes developed within this collaboration.
SOURCE: Evotec
Filed Under: Drug Discovery
